Anti-Ro False-Negatives Detection Through Anti-Ro52 KDa and Anti-Ro60 KDa Analysis in Systemic Lupus Erythematosus Patients

PS1:8

1E Grau, 1I Chalmeta Verdejo, 1E Labrador Sanchez, 2M Fernandez Matilla, 1FM Ortiz Sanjuan, 1CM Feced Olmos, 2N Fernandez-Llanio Cornella, 1K Arevalo Ruales, 1R Negueroles Albuixech, 1J Ivorra Cortes, 1J Frago Gil, 1I Martinez Cordellat, 1R Gonzalez Mazario, 1L Gonzalez Puig, 1C Alcañiz Escandell, 1C Najera Herranz, 1I Canovas Olmos, 1E Vicens Bernabeu, 1JE Oller Rodriguez, 1M de la Rubia Navarro, 1JA Castellano Cuesta, 2V Fornes Ferrer, 2D Hervas Marin, 3D Gimenez-Romero, 1JA Roman Ivorra. 1Rheumatology Department. HUP La Fe, Valencia, Spain; 1Rheumatology Section. Hospital Arnau de Vilanova, Valencia, Spain; 2Biostatistics Unit. IIS La Fe, Valencia, Spain; 3Physical-Chemistry Department. UV, Valencia, Spain

Purpose
The aim of the present study is to identify false-negatives for anti-Ro by analysing both 52 KDa and 60 KDa subunits separately, as well as to characterise if there are clinical or molecular differences in this subgroup of patients compared to anti-Ro negative cases.

Methods
A cross-sectional, observational study of patients diagnosed of SLE according to SLICC 2012 criteria was performed. In these patients a complete blood-test was made, and clinical data by personal interview was collected. INF1A, Anti-Ro, anti-Ro52KDa and anti-Ro60KDa levels where measured by colorimetric methods. Biostatistical analysis was performed with R 3.3.2.

Results
We selected 69 SLE patients with negative results for anti-Ro (2.34±4.17 U/mL) out of 142 total SLE patients. A total of 51 patients were negative for both anti-Ro subunits and 18 cases presented positive results (up to 20 pg/mL) for at least one of them (See table 1).

The subgroup of patients that exhibit simultaneously high levels of anti-Ro52KDa and anti-Ro60KDa have higher clinical activity compared to negative anti-Ro cases (75% of active patients against 41.2% in anti-Ro negative patients). However, no differences in the accumulated damage evaluated by SLICC score between negative anti-Ro cases and patients with at least one positive subunit were observed.

We analyse serum levels of INF1A cytokine in the four groups of patients, and anti-Ro and subunits negative cases showed significant lower INF1A levels than the other patients (8.26±14.87 pg/mL and 26.62±40.71 pg/mL respectively; p=0.04). In addition, patients with high levels of anti-Ro52KDa subunit are those with the highest INF1A levels (anti-Ro 52+/anti-Ro60- 23.5±47.6 pg/mL of INF1A; anti-Ro 52+/anti-Ro60+ 36.4±37.9 pg/mL of INF1A).

Conclusion
In our anti-Ro seronegative patients, a 26% of false-negative cases were detected. These cases with high levels of almost one anti-Ro subunit showed significantly higher levels of INF1A in contrast to negative cases, supporting the fact that they are indeed a different group from the negative cases. Moreover, the high INF1A levels could be the reason of the observed differences in the clinical activity measured by SLE-DAI score in both groups.

Abstract PS1:8 Table 1

<table>
<thead>
<tr>
<th>Antigen</th>
<th>NEGATIVES N=51</th>
<th>Anti-Ro52KDa POSITIVES N=8</th>
<th>Anti-Ro60KDa POSITIVES N=2</th>
<th>Anti-Ro52KDa / Anti-Ro60KDa POSITIVES N=8</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-Ro [U/mL]</td>
<td>(3.11)</td>
<td>(3.2)</td>
<td>(0.71)</td>
<td>(8.37)</td>
</tr>
<tr>
<td>Anti-Ro52 KDa [pg/mL]</td>
<td>(1.89)</td>
<td>(147.24 (74.25)</td>
<td>(0.89)</td>
<td>(50.06)</td>
</tr>
<tr>
<td>Anti-Ro60 KDa [pg/mL]</td>
<td>(2.71)</td>
<td>(6.3)</td>
<td>(7.01)</td>
<td>(76.69)</td>
</tr>
</tbody>
</table>
aim of our study is to investigate the value of B cells subsets as biomarkers in patients with active LN, in patients at the onset of renal manifestation or with renal flare, and finally in nephritic patients in relation to their clinical and laboratory characteristics at the baseline and during the course of the disease.

**Methods** 50 patients with active LN at disease onset or disease flare were enrolled and evaluated every three months. Laboratory, immunological and disease activity data were collected at the baseline and at 6(T6), 12(T12), 24(T24), 36(T36) months and at the last follow-up(FU).Number of renal flares, time to renal remission and persistent proteinuria at the last FU were considered. B cell subsets were evaluated at baseline through cytofluorimetry and classified using C27/IgD classification. The characterisation of B cells subsets was realised in 50 LN patients and 37 healthy controls.

**Results** LN patients had a lower percentage of CD19 + cells than controls(9.2% vs 10.6%; p=0.01) as well as a lower percentage of memory unswitched cells CD27 + IgD+(10.7% vs 15.3%; p<0.001) while LN patients had an higher percentage of plasmablasts and double negative memory cells CD27-IgD- (respectively 5.9% vs 1%; p<0.001 and 10.9% vs 4.1%; p=0.01). No significant differences regardless B cells subsets were found between early LN patients and long ones as well as between LN patients at the onset and LN patients during renal flare. We found a correlation between higher disease activity (assessed with SLEDAI 2K) and lower percentage of memory B cells IgD-CD27+(p=0.02). Double negative B cells CD27-IgD- tended to be correlated with a higher disease activity. Of interest the correlation between persistent proteinuria detected during the follow-up and a lower percentage of plasmablasts at the baseline (p=0.015).

**Conclusion** The alteration of B cells subsets is an early event in LN without differences regardless the timing of renal involvement (nephritic onset or later LN development). The association between persistent proteinuria and a lower percentage of plasmablasts at the baseline could be a negative prognostic factor considering the correlation between persistent proteinuria and worse renal outcome.

**PS1:11**

**THE INTERFERON BIOMARKER SIGLEC1 REFLECTS DISEASE ACTIVITY IN PAEDIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS**

1VS Sae Lim, 2J Klotsche, 3M Heinrich, 4J Thumfart, 5R Biesen, 6C Meisel, 7N Untenwalder, 1T Kallinich, 1Klinik für Pädiatrie, Sektion Rheumatologie, Charité, Berlin, Germany; 2Interdisziplinäres Sozialpädiatrisches Zentrum, Charité, Berlin, Germany; 3Deutsches Rheuma-Forschungszentrum und Universitätsmedizin, Charité, Berlin, Germany; 4Klinik für Pädiatrie, Sektion Nephrologie, Charité, Berlin, Germany; 5Fachbereich Immunologie, Labour Berlin-Charité, Vivantes, Berlin, Germany

**Introduction** SIGLEC1 (sialic acid-binding Ig-like lectin 1, CD169) is a monocytic adhesion molecule induced by interferon – α. In adult systemic lupus erythematosus (SLE), SIGLEC1 correlates cross-sectionally and longitudinally with disease activity. The aim of this work was to examine whether SIGLEC1 also reflects the disease activity in paediatric SLE.

**Methods** Over a period of 29 months the disease activity was clinically evaluated using SLEDAI (SLE-Disease Activity Index-2000). In 28 consecutive paediatric SLE patients (mean age 16 years, range 3–38 years, 86% female, 14% male), the number of SIGLEC1 molecules per CD14 + monocyte was quantified using flow cytometry. At the same time, the level of anti-ds DNA-antibody titre (ELISA) and the concentration of complement factors C3 and C4 (nephelometry) were determined. The association between SIGLEC1, C3, C4 and ds DNA-antibody with SLEDAI was estimated using a mixed linear model to model the repeated measurement of parameters within a patient. The cut-off for the change in SIGLEC1 between two consecutive visits to predict minimal clinical improvement or worsening in SLEDAI was chosen on the maximum Youden Index.